Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arena Pharmaceuticals (NQ: ARNA )

71.46 USD -2.11 (-2.87%)
Official Closing Price Updated: 4:10 PM EST, Mar 8, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Arena Pharmaceuticals

< Previous 1 2 3 4 5 Next >
Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a... 
From Business Wire News Releases
Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. 
From Business Wire News Releases
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to... 
From Business Wire News Releases
Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23
Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23. 
From Business Wire News Releases
Arena Pharmaceuticals Announces Changes to Board of Directors
Industry veteran Garry Neil, MD named Board Chair. Nawal Ouzren, CEO of Sensorion named to Board. 
From Business Wire News Releases
Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective,... 
From Business Wire News Releases
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to... 
From Business Wire News Releases
Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan... 
From PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to... 
From PR Newswire
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
- Data selected for late-breaker oral presentation on December 14 
From PR Newswire
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial
- Evaluating 2 mg etrasimod in study participants with moderately to severely active ulcerative colitis (UC) 
From PR Newswire
Arena Pharmaceuticals Announces R&D Leadership Transition
Arena Pharmaceuticals announces the appointment of Paul D. Streck, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer. 
From Business Wire News Releases
Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd... 
From PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020, the Compensation Committee of its Board of Directors granted to 13 new employees inducement stock options to... 
From PR Newswire
Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis
- Delivered compelling topline results from ADVISE Ph 2b trial evaluating etrasimod in atopic dermatitis; advancing into a Ph 3 registrational program 
From PR Newswire
Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
- Etrasimod 2 mg in the primary analysis achieved statistical significance of the registrational endpoint vIGA at week 12 
From PR Newswire
Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020, after the close of the U.S. financial... 
From PR Newswire
Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company
- Longboard Pharmaceuticals (formerly Arena Neuroscience) is an Arena-founded independent company focused on advancing promising investigational therapies for rare neurological diseases 
From PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on October 15, 2020, the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to... 
From PR Newswire
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community
- New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis 
From PR Newswire
Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome
- Evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C) or diarrhea (IBS-D) 
From PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on September 15, 2020, the Compensation Committee of its Board of Directors granted to nine new employees inducement stock options to... 
From PR Newswire
Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next... 
From PR Newswire
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC) 
From PR Newswire
Savvy Companies Eye Promising Potential in Multi-Billion-Dollar Industry
From CannabisNewsWire
Savvy Companies Eye Promising Potential in Multi-Billion-Dollar Industry
From InvestorBrandNetwork
Savvy Companies Eye Promising Potential in Multi-Billion-Dollar Industry
CannabisNewsWire Editorial Coverage 
From PR Newswire
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences: 
From PR Newswire
Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderate-to-severe alopecia areata 
From PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on August 15, 2020, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to... 
From PR Newswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.